Arsenal Capital Partners

What Arsenal Capital Partners does

Arsenal Capital Partners is a New York-based middle-market private equity firm founded in 2000 that builds market-leading companies in two specialized verticals: Healthcare and Industrial Growth. Across 25 years the firm has raised $10bn+ in institutional funds (Fund IV $1.3B in 2016, Fund V $2.36B in 2019, two new funds totaling $5.4B in 2022), executed 320+ platform and add-on transactions, and completed 35+ realizations to strategics and other sponsors including Henkel, Humana/CenterWell ($1B for MaxHealth), American Securities, Carlisle, Colorcon, Leggett & Platt, and KKR-affiliate Greenhill. The firm operates a platform-plus-add-on investment model anchored by Operating Partners, Investment Partners, Managing Directors, and a 60+ person Senior Advisor roster (including former FDA senior officials, Nobel laureates, and healthcare system executives).

The portfolio spans two broad franchises. The Healthcare franchise is anchored by pharma services (WCG, Certara, Lumanity, CellCarta, Endpoint Clinical, Rancho BioSciences) and healthcare technology and services (Hopebridge, Knowtion Health, 3DR Labs, OncoHealth, MaxHealth until its 2026 exit). The Industrial Growth franchise operates across innovative materials (Chroma Color, Meridian Adhesives, Polycorp), polymers and packaging (Fenzi, Polywood, Revolution, ThermoSafe), and industrial technologies (Headwall, Invio Automation). Notable 2024-2026 transactions include ThermoSafe ($725M from Sonoco), Knowtion Health (from Sunstone Partners, August 2024), POLYWOOD (with BayPine, March 2024), Polycorp (January 2024), and the announced majority acquisition of Velcro Companies from the Cripps Foundation (May 2026, Q4 2026 expected close).

Arsenal generates revenue through standard private equity fund economics — management fees on committed/invested capital across successive flagship funds plus carried interest from portfolio company realizations — supported by an institutional distribution channel of investment banks and legal advisors. In 2024 the firm formalized an internal Digital, AI, and Data Analytics Group and a Digital and AI Advisory Board to embed proprietary AI/data capabilities across sourcing, diligence, and value creation, while maintaining UN PRI signatory status (since February 2023), iCI membership, and SASB/TCFD alignment under a formal Responsible Investing Committee. Portfolio companies deploy domain technologies including AI-enabled revenue cycle management (Knowtion Health), biosimulation software (Certara), hyperspectral imaging (Headwall), agentic AI radiology workflows (3DR Labs/Strings), and AI-ready biomedical data curation (Rancho BioSciences).

Name

Arsenal Capital Partners

Legal name

Arsenal Capital Partners

Website

http://arsenalcapital.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

Arsenal Capital Partners is a New York-based middle-market private equity firm founded in 2000 that invests in Healthcare and Industrial Growth companies, with $10bn+ in institutional funds raised across 25 years and 35+ portfolio company realizations to strategics and sponsors.

Ownership category

akta.pro rank

Product category

Private Equity Fund Management

NAICS

Portfolio Management and Investment Advice (52394), Other Financial Vehicles (52599), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Multi-Sector / Generalist Growth Equity (FSANACAO)

akta.pro secondary industries

Industrials & Manufacturing Growth Equity (FSANACAF), Large-Cap / Mega-Fund Buyout (FSANABAA), Capital Raising Advisory (Debt/Equity/Private Capital) (BPAHADAG)

Keywords

• Private equity investment
• Middle-market buyouts
• Healthcare private equity
• Industrial growth investing
• Fund management

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Private equity fund management and carried interest: Arsenal generates revenue as a private equity investment firm by raising institutional equity investment funds (over $10 billion raised across its history) and earning management fees plus carried interest from limited partners across multiple funds (Fund IV $1.3B 2016, Fund V $2.36B 2019, two new funds totaling $5.4B closed in 2022).
2. Realizations through portfolio company exits: Arsenal realizes value through more than 35 completed exits of portfolio companies (e.g., Airnov to Colorcon, Seal For Life to Henkel, Applied Adhesives to Bertram Capital, Meridian Adhesives to American Securities, ATP to Henkel, MaxHealth to CenterWell/Humana, BioIVT to Linden, Cello Health, Elite Comfort Solutions to Leggett & Platt, Accella to Carlisle, Certara IPO with retained minority stake, IGM Resins to Astorg, Spartech to Nautic, Chromaflo to American Securities, Flowchem to KMG).
3. Co-investment and operating value creation: Arsenal partners with management teams and other investors (e.g., BayPine on POLYWOOD, Sunstone Partners on Knowtion Health, McKesson on OncoHealth, Leonard Green on WCG, Bregal Unternehmerkapital selling ATP to Arsenal) and captures economics through majority ownership, recapitalizations, and platform-plus-add-on strategies.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

Arsenal Capital Partners is a private equity investment firm that raises institutional capital through successive flagship funds and deploys that capital into majority buyouts, growth investments, and recapitalizations of middle-market healthcare and industrial growth companies. The firm operates two specialized franchises — Healthcare (pharma services and healthcare technology and services) and Industrial Growth (innovative materials, polymers and packaging, and industrial technologies) — and pursues value creation through platform-plus-add-on acquisition strategies supported by Operating Partners and a 60+ person Senior Advisor network.

Product overview

Arsenal Capital Partners operates a platform-plus-modules architecture as a private equity investment firm, organized around two specialized franchises: Healthcare and Industrial Growth. The core platform comprises the firm's investment teams, Operating Partners (e.g., George Abd, Jeremy Steinfink), Investment Partners (e.g., Gene Gorbach, Joe Rooney, Bradley Brown, Matthew Whitman), and a Digital, AI, and Data Analytics Group, with over $10 billion in institutional funds raised across 25+ years. The Healthcare module consists of portfolio companies operating in Pharma Services (CellCarta, Certara, Lumanity, WCG) and Healthcare Technology and Services (Hopebridge, Knowtion Health, MaxHealth, OncoHealth, 3DR Labs, Endpoint Clinical, Rancho BioSciences, TractManager), with 90% of all clinical trials in the U.S., 87% of all FDA-approved drugs, and 3,000+ hospitals and care providers connected to these companies. The Industrial Growth module operates across Innovative Materials (Chroma Color, Meridian Adhesives, Polycorp), Polymers and Packaging (Fenzi, Polywood, Revolution, ThermoSafe), and Industrial Technologies (Headwall, Invio Automation), with 35+ platforms and 150+ add-on acquisitions. Arsenal also runs an "EDAI" (Expert-Directed Applied Intelligence) platform at portfolio company Lumanity, which became the first life sciences value demonstration partner to achieve ISO 42001 certification, and a ClinSphere® AI engine at WCG that powers Trial IntelX™ for predictive trial design. The platform supports 320+ platform and add-on transactions, integrating acquired companies into cohesive operating units while leveraging a Responsible Investing Committee aligned with UN PRI, SASB, and TCFD standards.

Differentiator

Problem solved

Functional benefit

Brands

• Healthcare: Arsenal's dedicated healthcare private equity franchise investing in pharma services and healthcare technology and services (HCIT) companies.
• Industrial Growth

Products and services

• Arsenal Healthcare Private Equity Franchise Dedicated private equity franchise investing in middle-market healthcare companies across pharma services (clinical research, biosimulation, value demonstration) and healthcare technology and services (revenue cycle management, autism therapy, value-based primary care, oncology digital health), with healthcare portfolio companies reaching 90% of all clinical trials in the U.S., 87% of all FDA-approved drugs, and 3,000+ hospitals and care providers.
• Arsenal Industrial Growth Private Equity Franchise Dedicated private equity franchise investing in middle-market specialty industrial growth companies across Innovative Materials (Chroma Color, Meridian Adhesives, Polycorp), Polymers & Packaging (Fenzi, POLYWOOD, Revolution, ThermoSafe), and Industrial Technologies (Headwall, Invio Automation), with 35+ platforms and 150+ add-on acquisitions executed to date.
• Arsenal Capital Partners Flagship Investment Funds Successive institutional private equity fund vehicles (Fund IV, Fund V, and successor 2022 funds totaling $5.4B) through which Arsenal raises capital from institutional limited partners for investment into middle-market healthcare and industrial growth companies; cumulative $10bn+ in institutional funds raised since firm inception.

Quantifiable outcome

• 320+ platform and add-on transactions completed since inception
• +9 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

14 partnerships are on record, tiered flagship, core and minor.

• Kirkland & Ellis LLPflagshipImplementation/ SI/ Consulting Partner · 26 May 2026Kirkland & Ellis LLP served as legal counsel to Arsenal Capital Partners on the Velcro Companies acquisition and on multiple prior transactions (ThermoSafe, ATP, WCG deal work, Seal For Life).
• AltasciencescoreStrategic or Co-development Partner · 7 May 2026Altasciences and Certara (Arsenal portfolio company) announced a strategic partnership on May 7, 2026 to accelerate early drug development by integrating Certara's biosimulation into Altasciences' Acceleration Platform for sponsors.
• VeristatcoreStrategic or Co-development Partner · 22 April 2026Certara (Arsenal portfolio company) entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for up to $135 million on April 22, 2026, sharpening Certara's focus on Model-Informed Drug Development. Perella Weinberg Partners LP advised Certara; Guggenheim Securities advised Veristat.
• The Contract NetworkcoreStrategic or Co-development Partner · 21 April 2026WCG (Arsenal portfolio company) signed an agreement to acquire The Contract Network on April 21, 2026, extending ClinSphere's AI-driven site enablement capabilities across study start-up and contract/budget intelligence.
• Henkel AG & Co. KGaAflagshipStrategic or Co-development Partner · 1 April 2026Henkel signed an agreement to acquire Swiss-based ATP Adhesive Systems from Arsenal Capital Partners on January 16, 2026; transaction closed April 1, 2026. ATP employs ~700 people across Europe and North America with ~€270M expected FY2025 sales. Morgan Stanley & Co. LLC advised ATP, Kirkland & Ellis served as legal counsel.
• Humana Inc. (CenterWell)flagshipStrategic or Co-development Partner · 13 February 2026CenterWell, the healthcare services division of Humana Inc., completed its acquisition of MaxHealth from Arsenal Capital Partners on February 13, 2026 (deal valued at ~$1B per Bloomberg); MaxHealth operates 54 owned primary care clinics, 4 specialty clinics, and 24 affiliate clinics in Florida serving 120,000+ patients.
• Calvary Robotics Inc.flagshipStrategic or Co-development Partner · 2 February 2026Invio Automation (Arsenal portfolio company) acquired Calvary Robotics Inc., a robotics and advanced automation solutions provider headquartered in Webster, NY with additional locations in South Carolina and Malaysia. Houlihan Lokey served as exclusive financial advisor to Calvary Robotics.
• Bertram CapitalcoreStrategic or Co-development Partner · 14 November 2025Bertram Capital acquired a majority interest in APPLIED Adhesives from Arsenal Capital Partners on November 14, 2025, following APPLIED's strategic growth through 17 add-on acquisitions over the past four years.
• Sonoco Products CompanyflagshipStrategic or Co-development Partner · 3 November 2025Arsenal completed the acquisition of ThermoSafe from Sonoco for up to $725 million ($650M cash plus up to $75M additional consideration) on November 3, 2025. ThermoSafe is a global leader in temperature assurance technologies for pharmaceuticals and biologics with $240M+ in 2024 sales. Morgan Stanley advised Sonoco; Freshfields served as Sonoco legal counsel; Raymond James advised Arsenal; Kirkland & Ellis served as Arsenal legal counsel.
• Avery Dennison CorporationcoreStrategic or Co-development Partner · 25 August 2025Avery Dennison signed a definitive agreement to acquire Meridian's U.S. flooring adhesives business for $390 million on August 25, 2025. Meridian is an Arsenal portfolio company. Chemlink Partners and Goodwin Procter advised Avery Dennison; Piper Sandler, Moelis, and Weil Gotshal advised Meridian.
• BLK Capital Management, Synergist Network, Girls Who InvestminorOthers · 1 January 2025Arsenal has formed partnerships with BLK Capital Management, Synergist Network, and Girls Who Invest as part of its diversity and talent development initiatives referenced on the Talent & Culture page.
• UN Principles for Responsible Investment (PRI) / Initiative Climat International (iCI) / SASB / TCFDcoreOthers · 1 January 2025Arsenal is a signatory to the UN-supported Principles for Responsible Investment, a member of Initiative Climat International (iCI), a user of SASB standards, and aligned to the TCFD framework. Collaborations and memberships support Arsenal's formal Responsible Investing Committee led by Marion Hayes.
• American SecuritiesflagshipStrategic or Co-development Partner · 1 September 2022American Securities acquired Meridian Adhesives from Arsenal on September 1, 2022, marking a major exit for Arsenal's specialty adhesives platform.
• Autism Impact FundcoreStrategic or Co-development Partner · 24 May 2022Autism Impact Fund and Arsenal Capital Partners formed a strategic partnership on May 24, 2022, supporting Arsenal's portfolio company Hopebridge and the broader autism therapy services market.

Scale indicators17 records

Recent moves24 records

Expansion highlights6 records

Broad incumbents

• Blackstone: Mega-fund with dedicated healthcare and industrial growth strategies that increasingly compete in the middle-market segment Arsenal targets; relevant as a benchmark for fund-of-funds LPs evaluating Arsenal's middle-market exposure.
• KKR: Global private equity major with healthcare and industrial growth platforms; Bradley Brown joined Arsenal from KKR's Americas Private Equity technology team, signaling direct competition for talent and overlapping sector coverage at scale.

Direct peers

• Leonard Green & Partners: Middle-market private equity firm that partnered with Arsenal on the WCG recapitalization (November 2019); competes for similar consumer, healthcare, and business services transactions.
• Bertram Capital: Middle-market private equity firm that acquired Applied Adhesives from Arsenal in November 2025; focuses on industrial growth and business services transactions similar to Arsenal's Industrials franchise.
• Linden Capital Partners: Healthcare-focused middle-market private equity firm that acquired BioIVT from Arsenal in October 2021; competes directly with Arsenal's healthcare franchise for pharma services and healthcare technology deals.
• American Securities: Middle-market private equity firm that has acquired portfolio companies from Arsenal (Meridian Adhesives in 2022, Chromaflo Technologies in 2016) and competes for similar industrial growth and healthcare transactions.
• Bregal Unternehmerkapital: European middle-market private equity firm that sold ATP Group to Arsenal in February 2022; operates a comparable sector-specialist buyout model with industrial growth focus.
• Angeles Equity Partners: Middle-market private equity firm focused on industrial growth and niche manufacturing; Max Schechter joined Arsenal from Angeles in June 2026 after leading business development there for nearly two decades, indicating comparable deal sourcing and operating playbooks.
• Audax Group: Middle-market private equity firm executing a comparable platform-plus-add-on buyout strategy; Arsenal previously sold Source Refrigeration & HVAC to Audax, and both firms compete for similar lower-middle-market industrial and business services transactions.
• BayPine: Growth-oriented middle-market private equity firm that partnered with Arsenal on the POLYWOOD acquisition (March 2024); shares Arsenal's focus on industrial growth and platform-building strategies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/arsenal-capital-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries24 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A43 records

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arsenal Capital Partners